Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

OncoMed Pharmaceuticals  (Stock symbol: OMED ) Acquired by Mereo BioPharma Group (2019  amount undisclosed )

800 Chesapeake Drive
Redwood City, CA 94063
USA
650-995-8200
Website Company Summary Management Team
Board

Outside board: (May no longer be on the board) Rick E Winningham (Theravance Biopharma CEO/Chairman) Perry A Karsen (Pearl Therapeutics Former CEO) Jonathan Root (U.S. Venture Partners);  Lawrence A Lasky (Latterell Venture Partners) Jack W Lasersohn (The Vertical Group);  Deepa R Pakianathan (Delphi Ventures General Partner) Terry Gould (Adams Street Partners General Partner) Denise Scots-Knight (Mereo BioBiopharma CEO) Michael Wyzga (Radius Health Former CEO/President)
Former outside board: Atul Kapadia (Bay Partners General Partner) Alan C Mendelson (Latham & Watkins) Jim Broderick (Morgenthaler Ventures) James N Woody (OncoMed Pharmaceuticals Former President/CEO) Denise Pollard-Knight (Nomura Phase4 Ventures Managing Director)
Company

Business description: OncoMed is a US-based clinical stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics. OncoMed currently has three therapeutic candidates in development (Phase 1/1b). OncoMed currently has a strategic alliance with Celgene and milestone payments and investments from this collaboration (and prior collaborations with GlaxoSmithKline LLC and Bayer Pharma AG) have supported the advancement and growth of its product pipeline.
Partners include: GlaxoSmithKline Standard BioTools ;  Bayer HealthCare ;  Bayer Schering Pharma ;  MorphoSys
Capital

Rounds: 2
Recent Fundings: Dec 2013   Apr 2011
Capital raised: 210.1M
Last Round: 22.2M
Ownership: Acquired by Mereo BioPharma Group (2019  amount undisclosed ) Ipo Filing
Stock Symbol: OMED

Last Tweets


 

Last Mentions


Overview
Record updated: Dec 2018
Sector: Medical
Year Founded: 2004
Headcount: 76-100 as of Dec 2018
Rounds: 2
Recent Fundings: Dec 2013   Apr 2011
Capital Raised: 210.1M
Last Round: 22.2M
Ownership: Acquired by Mereo BioPharma Group (2019  amount undisclosed ) Ipo Filing
Stock Symbol: OMED